Rituximab: anti-CD20 monoclonal antibody (Rituxan, MabThera, biosimilars)

This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions. Reserve Meds does not make insurance or pharmacy-assistance-program promises.

Ask about Rituximab

Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.

Medicine

CountryChoose your countrySaudi ArabiaUnited Arab EmiratesKuwaitQatarBahrainOmanIndiaPakistanOther

WhatsApp number

Country codeUnited Arab Emirates +971Saudi Arabia +966Kuwait +965Qatar +974Bahrain +973Oman +968Jordan +962Lebanon +961Egypt +20Iraq +964India +91Pakistan +92Turkey +90United Kingdom +44United States / Canada +1

We reply on WhatsApp.

Email (optional)

Message (optional)

Website

Send my questionMessage us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Already have a case? Sign in

What rituximab is

Rituximab is a chimeric mouse-human IgG1 monoclonal antibody that targets the CD20 antigen, a transmembrane phosphoprotein expressed on the surface of B-lymphocytes from the pre-B-cell stage through to mature memory B cells. It does not bind plasma cells or haematopoietic stem cells. The originator was developed at IDEC Pharmaceuticals and Genentech and received its first US FDA approval in 1997 under the brand name Rituxan, the earliest monoclonal antibody approved for any oncology indication. It is marketed in the European Union as MabThera, with FDA-approved biosimilars Truxima (Celltrion), Ruxience (Pfizer), and Riabni (Amgen).

Mechanistically, rituximab depletes CD20-positive B cells through three pathways: complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) via natural killer cells and macrophages, and direct induction of apoptosis. The downstream effect is loss of B-cell-driven malignancy (in non-Hodgkin lymphoma and chronic lymphocytic leukemia) or B-cell-driven autoimmunity (in rheumatoid arthritis, the ANCA-associated vasculitides, pemphigus vulgaris, multiple sclerosis, and a number of off-label uses). B-cell recovery typically begins six to nine months after treatment and is complete within a year for most patients, though immunoglobulin levels can remain suppressed for longer.

Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.

FDA-approved indications

Per the US Prescribing Information for Rituxan (Genentech), rituximab is approved in adults for the following indications:

• Non-Hodgkin lymphoma (NHL). Relapsed or refractory low-grade or follicular CD20-positive B-cell NHL as a single agent; previously untreated follicular CD20-positive B-cell NHL in combination with first-line chemotherapy and as single-agent maintenance therapy; non-progressing low-grade CD20-positive B-cell NHL after first-line CVP chemotherapy; previously untreated diffuse large B-cell CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens.
• Chronic lymphocytic leukemia (CLL). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
• Rheumatoid arthritis (RA). Moderately to severely active RA in adult patients who have had an inadequate response to one or more TNF antagonist therapies, in combination with methotrexate.
• Granulomatosis with polyangiitis (GPA, formerly Wegener) and microscopic polyangiitis (MPA). Adult patients with GPA or MPA, in combination with glucocorticoids.
• Pemphigus vulgaris (PV). Adult patients with moderate to severe PV.

The MabThera EU Summary of Product Characteristics (European Medicines Agency, EPAR) tracks the US label on the major haematology and rheumatology indications, with regional formulation differences.

Off-label uses

Outside the licensed indications above, rituximab has accumulated substantial clinical evidence in a range of B-cell-driven disorders. Off-label use is not endorsed by the manufacturer and is the prescribing physician's clinical decision; it is summarised here because cross-border patient requests frequently arise from off-label indications.

• Multiple sclerosis (MS). Rituximab is not FDA-approved for MS but is widely used in relapsing and progressive disease. The phase 2 HERMES trial (Hauser SL et al., N Engl J Med 2008;358(7):676-688) showed significant reduction in gadolinium-enhancing lesions and clinical relapses in relapsing-remitting MS. It is incorporated into Swedish, Norwegian, and many other international neurology protocols as a clinically established option, particularly where ocrelizumab is not available or not funded. Dosing protocols vary; common regimens use 1000 mg IV on Day 1 and Day 15 followed by 500 to 1000 mg every six months.
• Immune thrombocytopenia (ITP). Second-line option in adult chronic ITP per international consensus reports.
• Warm autoimmune haemolytic anaemia (warm AIHA). Widely used as a second-line option after corticosteroids; supported by haematology guidelines including those of the British Society for Haematology.
• Lupus nephritis and refractory systemic lupus erythematosus (SLE). Used in patients refractory to standard induction; the LUNAR and EXPLORER trials did not meet primary endpoints but real-world evidence and consensus protocols continue to support its use in selected patients.
• Neuromyelitis optica spectrum disorder (NMOSD). Established off-label option for relapse prevention in aquaporin-4 antibody-positive NMOSD, with multiple prospective and retrospective series supporting use.
• Other. IgG4-related disease, myasthenia gravis (particularly MuSK-antibody positive), thrombotic thrombocytopenic purpura, mixed cryoglobulinaemia, and a number of paediatric rheumatology indications.

Dosing

Dosing varies materially by indication; the regimens below are illustrative and should be confirmed against the current US Prescribing Information for Rituxan or the relevant national label by the treating physician. Reserve Meds does not prescribe.

• Non-Hodgkin lymphoma. 375 mg/m squared body surface area, intravenously, weekly for four to eight infusions depending on protocol; maintenance regimens dose every two to three months.
• Chronic lymphocytic leukemia. 375 mg/m squared on the day prior to FC chemotherapy in cycle 1, then 500 mg/m squared on Day 1 of cycles 2 through 6.
• Rheumatoid arthritis (RA). 1000 mg IV on Day 1 and Day 15 as a course; subsequent courses every 24 weeks (six months) or based on clinical evaluation, but no sooner than every 16 weeks.
• Granulomatosis with polyangiitis and microscopic polyangiitis. Induction: 375 mg/m squared IV once weekly for four weeks, in combination with glucocorticoids. Follow-on dosing per current label.
• Pemphigus vulgaris. 1000 mg IV on Day 1 and Day 15, then 500 mg IV at month 12 and every six months thereafter, with a tapering course of glucocorticoids.
• Multiple sclerosis (off-label). No FDA-approved regimen. Common protocols in clinical use are 1000 mg IV on Day 1 and Day 15 as an induction course, followed by 500 to 1000 mg every six months. Some centres use 500 mg IV every six months for maintenance after induction.

Premedication is required with intravenous methylprednisolone 100 mg (or an equivalent glucocorticoid), an antihistamine (commonly diphenhydramine), and acetaminophen (paracetamol). The first infusion is the highest-risk window for infusion-related reactions; rate titration is standard. All patients should be screened for hepatitis B before the first dose, and live vaccines should not be administered during or shortly after rituximab therapy.

Access through Reserve Meds

Reserve Meds coordinates US-sourced rituximab (Rituxan) for international patients through doctor-directed named-patient or personal-import pathways. Country-specific access guides are published as each market matures; additional guides will follow the India launch.

• Rituximab access guide: India
• Named-patient and personal-import pathways: overview
• Rituxan brand-name page (US-sourced supply)

Patients in the UAE, Saudi Arabia, Egypt, Pakistan, the United Kingdom, and other markets we serve can submit an intake, and the case is coordinated under the same workflow with your treating doctor.

How Reserve Meds coordinates supply

Every rituximab case follows the same doctor-directed, document-first workflow:

1. The treating physician issues a prescription and clinical justification letter, including indication, dosing schedule, and (where relevant) off-label rationale.
2. Reserve Meds clinical and regulatory review assesses indication fit, destination-country pathway eligibility, and any biosimilar-versus-originator considerations the prescriber has raised.
3. Country-specific named-patient or personal-import documentation is prepared, translated where required, and submitted to the destination-country regulator under the local lawful import framework.
4. Supply is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability and an unbroken chain of custody from US warehouse forward.
5. Cold-chain handling is validated end-to-end with temperature monitoring and audit logs; rituximab is a refrigerated biologic.
6. Shipment is coordinated to the treating physician or hospital pharmacy, not directly to consumers.

Reserve Meds does not handle controlled substances and does not promise pharmacy assistance program enrollment, manufacturer copay support, or insurance reimbursement; those are commercial frameworks aimed at US-domiciled patients.

Biosimilars and the originator

Three rituximab biosimilars are FDA-approved in the United States: Truxima (rituximab-abbs, Celltrion), Ruxience (rituximab-pvvr, Pfizer), and Riabni (rituximab-arrx, Amgen). Additional biosimilars are approved in the European Union and other markets. Biosimilars are licensed on demonstrated equivalence in efficacy, safety, immunogenicity, and pharmacokinetics; they are not generics in the small-molecule sense. Patients who are stable on the originator and whose physicians prefer continuity may route to US-sourced Rituxan via named-patient import rather than switch to a biosimilar in the destination market; this is a treating-physician decision and Reserve Meds supports either path on physician request.

Frequently asked questions

Is rituximab the same as Rituxan?

Rituximab is the international nonproprietary name (INN) for the active ingredient; Rituxan is the originator brand name in the United States. MabThera is the originator brand name in the European Union. Truxima, Ruxience, and Riabni are FDA-approved biosimilars of the same active ingredient. All deliver rituximab as their active drug substance.

Why is rituximab used off-label for multiple sclerosis when ocrelizumab is FDA-approved?

Ocrelizumab (Ocrevus) is a humanised anti-CD20 monoclonal antibody specifically approved for relapsing and primary progressive MS. Rituximab is used off-label in MS for several reasons: longer real-world experience and the option of US-sourced supply via named-patient import where ocrelizumab is not accessible. The HERMES trial (Hauser SL et al., NEJM 2008) and decades of registry data underpin the clinical use.

What is the hepatitis B boxed warning about?

Rituximab can reactivate hepatitis B virus in patients with prior or active infection, in some cases leading to fulminant hepatitis and death. Pre-treatment HBV screening (HBsAg and anti-HBc at minimum) is mandatory for every patient; HBV carriers require monitoring during and after treatment.

Does rituximab require cold-chain handling?

Yes. Rituximab is a refrigerated biologic and requires temperature-controlled storage from manufacture through to administration. Reserve Meds operates DSCSA-compliant US sourcing with end-to-end cold-chain documentation.

How are infusion reactions managed?

Premedication with intravenous methylprednisolone, an antihistamine, and acetaminophen (paracetamol) is standard. The first infusion is titrated slowly and the patient is monitored closely; serious reactions trigger interruption or discontinuation. Approximately 80 percent of severe infusion reactions occur with the first infusion (per the US Prescribing Information).

Can I get rituximab through Reserve Meds in my country?

Reserve Meds publishes a country access guide for rituximab in India. Patients in other markets can submit an intake, and the case is coordinated under the same workflow with your treating doctor.

Does Reserve Meds prescribe rituximab?

No. Reserve Meds does not prescribe and does not substitute for the treating physician. The prescription, indication, dose, and clinical monitoring plan are the treating physician's responsibility.

Next step

Submit a 60-second intake. Our clinical team will respond with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote once your physician documentation is reviewed.

Ask about a medicine Or message us on WhatsApp